Celon Pharma S.A. Inhaber-Aktien ZY -,10
- BID
4.725
- ASK
4.915
- 423 Units407 Units
- 07/21, 11:30:28 AM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
14.47%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.35 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 4.73 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 11:17:46 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 4.73 | 4.6 |
| PREV. DAY'S PRICE | 4.61 | (07/20) |
| CHANGE DAY BEFORE | +0.12 | 2.60 % |
| 52 WEEK HIGH / LOW | 5.62 (02/26) | 4.24 (12/23) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.12 | -0.15 | -0.35 | -0.14 | 0.05 |
DIVIDENDS PER SHARE | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.52 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | 2.91 % | -100.00 % | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | 105.50 |
PRICE - BOOK RATIO | 1.77 | 3.20 | 3.02 | - | - |
PRICE - SALES RATIO | 4.73 | 7.73 | 5.15 | - | - |
PRICE - CASH FLOW RATIO | - | - | 45.31 | - | - |
Master Data
| WKN | A2DJW6 |
| ISIN | PLCLNPH00015 |
| SYMBOL | 8RP |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | CELON PHARMA S.A. ZY-,10 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 6.84 % | 1.88 % | -2.74 % | -2.12 % | -14.47 % | 27.70 % | -40.97 % | 4.54 % |
| HIGH | 4.79 | 4.79 | 5.05 | 5.62 | 5.62 | 7.32 | 9.00 | 5.62 |
| LOW | 4.28 | 4.28 | 4.28 | 4.28 | 4.24 | 3.05 | 2.38 | 4.28 |
Dividende
pro Aktie
Company profile
Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm's products include Aromek, Donepex, Ketrel, Salmex, and Valzek. It operates through the Generic Drug and Innovative segments. The Generic Drug segment pertains to the manufacture and sale of drugs registered and authorized for marketing. The Innovative segment involves activities that develop the documentation on the basis of which a drug could be registered or commercialized at the stage prior to drug registration. The company was founded by Maciej Wieczorek on June 20, 2002 and is headquartered in Lomianki, Poland.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.